Table 1.
Baseline Clinical Characteristics and Risk Factors
| Overall | Non RIPC | RIPC | P-Value | |
|---|---|---|---|---|
| # Patients | 150 | 58 | 92 | |
| Demographics | ||||
| Age (Years) | 62.0 (54.0–70.0) | 61.5 (54.0–70.0) | 62.0 (53.5–71.0) | 0.922 |
| Gender (% Male) | 111 (74.0%) | 46 (79.3%) | 65 (70.7%) | 0.239 |
| Height (cm) | 173 (163–180) | 173 (170–178) | 173 (163–180) | 0.251 |
| Weight (kg) | 84.5 (75.0–100) | 83.5 (76.0–100) | 86.0 (73.5–100) | 0.769 |
| Body Mass Index | 29.1 (25.5–34.0) | 27.5 (24.3–34.0) | 29.5 (26.4–34.2) | 0.071 |
| Race | 0.724 | |||
| White | 145 (96.7%) | 57 (98.3%) | 88 (95.7%) | |
| Black | 3 (2.0%) | 1 (1.7%) | 2 (2.2%) | |
| Asian | 1 (0.7%) | 0 (0.0%) | 1 (1.1%) | |
| Other | 1 (0.7%) | 0 (0.0%) | 1 (1.1%) | |
| Insurance | 0.658 | |||
| Private | 77 (51.3%) | 29 (50.0%) | 48 (52.2%) | |
| Public | 59 (39.3%) | 22 (37.9%) | 37 (40.2%) | |
| None | 14 (9.3%) | 7 (12.1%) | 7 (7.6%) | |
| Medical History | ||||
| Hypertension | 85 (56.7%) | 36 (62.1%) | 49 (53.3%) | 0.289 |
| Dyslipidemia | 74 (49.3%) | 30 (51.7%) | 44 (47.8%) | 0.642 |
| Current Dialysis | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Chronic Lung Disease | 7 (4.7%) | 3 (5.2%) | 4 (4.3%) | 0.845 |
| Diabetes | 30 (20.0%) | 7 (12.1%) | 23 (25.0%) | 0.054 |
| Prior Myocardial Infarction | 22 (14.7%) | 11 (19.0%) | 11 (12.0%) | 0.237 |
| Prior Heart Failure | 5 (3.3%) | 2 (3.4%) | 3 (3.3%) | 0.950 |
| Prior Percutaneous Coronary Intervention | 25 (16.7%) | 13 (22.4%) | 12 (13.0%) | 0.134 |
| Prior Coronary Artery Bypass Graft | 6 (4.0%) | 2 (3.4%) | 4 (4.3%) | 0.784 |
| Prior Atrial fibrillation | 5 (3.3%) | 1 (1.7%) | 4 (4.3%) | 0.383 |
| Prior Stroke | 5 (3.3%) | 2 (3.4%) | 3 (3.3%) | 0.206 |
| Prior Peripheral Artery Disease | 3 (2.0%) | 1 (1.7%) | 2 (2.2%) | 0.848 |
| Home Medications | ||||
| Aspirin | 45 (30.0%) | 21 (36.2%) | 24 (26.1%) | 0.188 |
| Clopidogrel | 8 (5.3%) | 3 (5.2%) | 5 (5.4%) | 0.945 |
| Prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Ticargrelor | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Warfarin | 3 (2.0%) | 1 (1.7%) | 2 (2.2%) | 0.848 |
| Beta blocker | 31 (20.7%) | 14 (24.1%) | 17 (18.5%) | 0.405 |
| Angiotensin Converting Enzyme Inhibitor | 24 (16.0%) | 8 (13.8%) | 16 (17.4%) | 0.558 |
| Angiotensin Receptor Blocker | 9 (6.0%) | 2 (3.4%) | 7 (7.6%) | 0.289 |
| Aldosterone Blocking Agent | 3 (2.0%) | 2 (3.4%) | 1 (1.1%) | 0.314 |
| Statin | 31 (20.7%) | 13 (22.4%) | 18 (19.6%) | 0.675 |
Continuous variables presented as median (IQR) and categorical variables presented as n (%).